Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + radiotherapy
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (cetuximab), External (radiotherapy)
01
Overview
Cetuximab + radiotherapy refers to the concurrent use of the monoclonal antibody **cetuximab** in combination with **radiotherapy**. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor that blocks ligand-induced phosphorylation of EGFR, thereby inhibiting downstream signaling pathways critical for cell proliferation and survival. When combined with radiotherapy, cetuximab acts as a radiosensitizer—enhancing the cytotoxic effect of radiation on tumor cells. This combination has demonstrated benefit in the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck and has also been investigated in non-small cell lung cancer (NSCLC), particularly in patients who are not candidates for chemoradiation[1][2][3][4].
- Other names
- Cetux-RTBRTBio-Radiotherapy
02
Targets
Beyond the preview
Go deeper on cetuximab + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + radiotherapy.